Company to investigate whether precisely programmed bioelectric stimulation can increase extracellular-vesicle production, optimize regenerative cargo and improve therapeutic activity
HUNTINGTON BEACH, Calif. — August 26, 2026 — Lionheart Health, Inc., a regenerative health and bioelectric medicine company, today announced the filing of a new provisional patent application and the launch of a research program focused on Bioelectrically Enhanced Exosomes™, an emerging approach designed to investigate whether precisely programmed electrical stimulation can improve the production, composition and regenerative activity of exosomes and other extracellular vesicles.
The research initiative builds upon a growing body of scientific evidence indicating that electrical stimulation can influence extracellular-vesicle biogenesis, secretion and molecular cargo, including proteins, microRNAs and other signaling molecules involved in tissue repair, inflammation, angiogenesis, metabolism and cellular communication.
“Our goal is to move beyond simply administering exosomes and investigate whether we can intelligently program the cells that produce them and the tissues that receive them,” said Howard J. Leonhardt, Executive Chairman and Co-CEO of Lionheart Health. “We believe bioelectric signaling may provide an important new tool for creating more precisely characterized regenerative extracellular-vesicle therapies.”
A Two-Stage Bioelectric Exosome Strategy
The Lionheart research program is designed around two complementary areas of investigation:
1. Bioelectric preconditioning of exosome-producing cells
Lionheart researchers plan to evaluate defined bioelectric stimulation protocols applied to mesenchymal stromal/stem cells and other selected cell populations before extracellular-vesicle collection.
The research will investigate whether particular stimulation parameters can:
- Increase extracellular-vesicle/exosome production.
- Modify protein and microRNA cargo.
- Enhance angiogenic and tissue-repair signaling.
- Improve mitochondrial and metabolic signaling.
- Enhance neurotrophic signaling.
- Modulate inflammatory signaling.
- Improve cell-protective and regenerative activity.
Candidate pathways and biomarkers for investigation may include VEGF, SDF-1/CXCR4, BDNF, PI3K/AKT, MAPK, mitochondrial signaling and other regenerative pathways.
2. Bioelectric conditioning of recipient tissue
A second research track will investigate whether targeted bioelectric stimulation before, during or after extracellular-vesicle administration can create a more favorable regenerative environment in recipient tissues.
Potential mechanisms under investigation include modulation of cellular membrane potential, calcium signaling, circulation, cellular metabolism, inflammation, gene expression and tissue-repair pathways.
The resulting concept can be summarized as:
Producer Cell → Precision Bioelectric Stimulation → Characterized Enhanced Exosome/EV Cargo → Delivery → Bioelectric Conditioning of Target Tissue → Regenerative Response
Developing Application-Specific Exosome Profiles
An important objective of the program will be determining whether different bioelectric stimulation parameters can produce measurably different extracellular-vesicle profiles.
Lionheart intends to investigate the potential development of application-specific protocols directed toward:
- Angiogenesis and circulation
- Muscle regeneration and healthy aging
- Brain and neurological health
- Mitochondrial and metabolic health
- Inflammation modulation
- Skin and hair regeneration
- Joint and orthopedic tissue repair
- Cardiovascular regeneration
Rather than assuming that electrical stimulation universally improves exosomes, Lionheart plans to characterize each experimental condition using objective laboratory measurements.
Comprehensive Exosome Characterization Program
Planned research may compare unstimulated control extracellular vesicles with vesicles produced under multiple bioelectric stimulation conditions.
Testing is expected to include, as appropriate:
Particle concentration and size distribution | CD9 | CD63 | CD81 | Proteomics | microRNA profiling | Lipidomics | Cellular uptake | Angiogenesis assays | Mitochondrial function | Oxidative stress | Inflammatory markers | Cell survival | Tissue-specific functional assays
The company believes this systematic approach could help identify which electrical parameters produce the most promising biological profiles and whether those effects are reproducible.
Building on Lionheart’s Bioelectric Medicine Platform
The new research initiative is designed to complement Lionheart Health’s broader work in programmable bioelectric signaling, regenerative medicine, stem-cell signaling, healthy longevity and tissue restoration.
Lionheart’s research strategy is based on the concept that regenerative medicine may increasingly involve not only delivering cells, proteins or extracellular vesicles, but also controlling the biological instructions cells receive before and after those regenerative agents are delivered.
“The future may be less about administering a generic regenerative product and more about delivering the right biological message, with the right cargo, to the right tissue at the right time,” Leonhardt stated. “Precision bioelectric signaling gives us another potentially powerful variable to investigate.”
Intellectual Property Program
The newly filed provisional patent application is intended to establish intellectual-property protection around aspects of Lionheart’s proposed combinations of bioelectric stimulation, extracellular-vesicle production and conditioning, cargo optimization, delivery protocols and recipient-tissue stimulation, subject to patent examination, prior art and subsequent filings.
Lionheart expects the research program to generate additional data that may support future patent filings and potential therapeutic and wellness applications.
Scientific Development Status
The company emphasizes that Bioelectrically Enhanced Exosomes™ is presently a research-stage platform. Although published preclinical studies from independent researchers provide encouraging evidence that electrical stimulation can alter extracellular-vesicle secretion and biological characteristics, individual Lionheart protocols and proposed therapeutic applications require laboratory characterization, validation and, where applicable, appropriate regulatory review before clinical claims can be made.
About Lionheart Health, Inc.
Lionheart Health, Inc. is developing a portfolio of bioelectric, regenerative and healthy-longevity technologies designed to support tissue repair and healthy aging. Its research programs combine programmable bioelectric stimulation with regenerative biologics, cellular signaling, physical conditioning and objective biomarker measurement.
The company’s broader research interests include muscle health, brain health, cardiovascular regeneration, joint health, hair and skin regeneration, vision health, metabolic health, sexual health, inflammation modulation and healthy longevity.
Forward-Looking Statements
This press release contains forward-looking statements regarding research programs, intellectual property, product concepts, potential biological mechanisms and prospective therapeutic applications. These statements involve risks and uncertainties, and actual results may differ materially. Research-stage technologies described herein have not necessarily been demonstrated to be safe or effective for the applications discussed and may require additional preclinical studies, clinical trials and regulatory authorization before commercialization for medical indications.
Media / Corporate Contact
Lionheart Health, Inc.
Huntington Beach, California
www.LionheartLongevity.com
Email: Howard@LeonhardtVentures.com